PDCD1 and type 1 diabetes mellitus: Interestingly, using an antibody that specifically disrupts TCR interactions with insulin peptide:MHC II complex, reduced the effects of PD-1 blockade on insulin-reactive B cell expansion but did not impact T1D incidence (61).